Experts Discuss Lessons From A-Fib Ablation Trials At Boston Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA will likely require future trials of atrial fibrillation (AF) ablation catheters to use an approved ablation catheter instead of antiarrhythmic drugs as the studies' control, experts suggested at the Boston Symposium on Atrial Fibrillation Jan. 15-17